These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15118478)

  • 21. Divalproex extended-release in acute bipolar II depression.
    Wang PW; Nowakowska C; Chandler RA; Hill SJ; Nam JY; Culver JL; Keller KL; Ketter TA
    J Affect Disord; 2010 Jul; 124(1-2):170-3. PubMed ID: 19923006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
    Dutta S; Zhang Y
    Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-Drug Interaction Studies of Paliperidone and Divalproex Sodium Extended-Release Tablets in Healthy Participants and Patients with Psychiatric Disorders.
    Remmerie B; Ariyawansa J; De Meulder M; Coppola D; Berwaerts J
    J Clin Pharmacol; 2016 Jun; 56(6):683-92. PubMed ID: 26412032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid oral loading of extended release divalproex in patients with acute mania.
    Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D
    Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release divalproex in child and adolescent outpatients with epilepsy.
    Kernitsky L; O'Hara KA; Jiang P; Pellock JM
    Epilepsia; 2005 Mar; 46(3):440-3. PubMed ID: 15730542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
    Simeon D; Baker B; Chaplin W; Braun A; Hollander E
    CNS Spectr; 2007 Jun; 12(6):439-43. PubMed ID: 17545954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
    Centorrino F; Kelleher JP; Berry JM; Salvatore P; Eakin M; Fogarty KV; Fellman V; Baldessarini RJ
    Am J Psychiatry; 2003 Jul; 160(7):1348-50. PubMed ID: 12832255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerability of divalproex sodium in elderly psychiatric patients with mixed diagnoses.
    Puryear LJ; Kunik ME; Workman R
    J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):234-7. PubMed ID: 8561838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder.
    Ravindran A; Silverstone P; Lacroix D; van Schaick E; Vermeulen A; Alexander J
    Clin Pharmacokinet; 2004; 43(11):733-40. PubMed ID: 15301577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis.
    Zhang CQ; Bai XY; Wan Y; Li HY; Sun H
    Medicine (Baltimore); 2021 Dec; 100(50):e28290. PubMed ID: 34918705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs.
    Sommerville KW; Dutta S; Biton V; Zhang Y; Cloyd JC; Uthman B
    Clin Drug Investig; 2003; 23(10):661-70. PubMed ID: 17535081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
    Pierre-Louis SJ; Brannegan RT; Evans AT
    Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder.
    Redden L; DelBello M; Wagner KD; Wilens TE; Malhotra S; Wozniak P; Vigna NV; Greco N; Kovacs X; Abi-Saab W; Saltarelli M;
    J Child Adolesc Psychopharmacol; 2009 Feb; 19(1):83-9. PubMed ID: 19232026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
    Wassef AA; Winkler DE; Roache AL; Abobo VB; Lopez LM; Averill JP; Mian AI; Overall JE
    Am J Psychiatry; 2005 Feb; 162(2):330-9. PubMed ID: 15677599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.